Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2025 09:14 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

All resolutions were approved MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the...
February 27, 2025 16:03 ET | Source: Oryzon Genomics, S.A.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024

Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreachPreparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in...
February 14, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences

The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder...
January 27, 2025 09:31 ET | Source: Oryzon Genomics, S.A.

ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting

Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics,...
January 23, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015,...
January 21, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor

MADRID, Spain and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to...
January 13, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia

Study conducted under the CRADA agreement between NCI and Oryzon MADRID, Spain and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a...
January 10, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Provide Corporate Progress Updates at Several Events in January-February

8th Sachs Annual Neuroscience Innovation Forum14th Annual LifeSci Advisors Corporate Access EventInvest Securities BioMed Forum 2025MidCap Events Frankfurt 2025Bio-Neuroscience 2025 MADRID and...
December 02, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat

MADRID and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
October 24, 2024 12:08 ET | Source: Oryzon Genomics, S.A.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024

Final data from PORTICO, global Phase IIb vafidemstat trial in BPD, presented at the 37th ECNP annual conference in SeptemberCompany moving forward with PORTICO-2 Phase III trial preparations...